MRI in MS: A Picture Worth a Thousand Words
Thursday, February 18th, 2021
BNAC Winter 2021 Newsletter
Wednesday, January 27th, 2021
We are pleased to present our BNAC Newsletter, a periodic publication about the work of our Center. This issue includes updates about our latest research, the academic and educational achievements of our staff, and information about our work as a core laboratory providing analysis services around the world.
Aubagio slows grey matter, whole brain atrophy in CIS, study finds.
Wednesday, December 2nd, 2020
Research Studies Progression of Neurodegeneration in MS
Tuesday, November 17th, 2020
Robert Zivadinov, MD, PhD, Discusses MS Fatigue
Sunday, November 15th, 2020
TCT Connect 2020: REFLECT II trial assess TriGuard 3 embolic protection device in TAVI patients
Thursday, October 15th, 2020
Distinctive contrast enhancement patterns identified in MS over time
Friday, September 11th, 2020
AAN 2020: Deep Grey Matter Structure and Perfusion Are Related to Cognition in Multiple Sclerosis
Tuesday, April 28th, 2020
Researchers Study Brain Atrophy of Aging MS Patients
Tuesday, April 7th, 2020
People with MS are living longer. How does neurodegeneration in these patients change as they age?
Wednesday, March 4th, 2020
High-tech scanning technology available to investigators
Tuesday, December 17th, 2019
Finding a Better MRI Marker for MS Disability Progression
Tuesday, November 12th, 2019
UB researchers discover clues to boost MS diagnosis, treatment
Wednesday, September 25th, 2019
A better MRI marker for disability progression in MS
Wednesday, September 25th, 2019
Study Addresses Use of GBCAs in Multiple Sclerosis Patients
Tuesday, July 30th, 2019
Comprehensive study of 21 retired NFL and NHL players doesn't find evidence of early onset dementia
Tuesday, August 7th, 2018
Brain iron levels may predict multiple sclerosis disabilities
Tuesday, July 17th, 2018
With Another Phase III Trial, BNAC Solidifies Imaging Expertise
Monday, June 5th, 2017
UB’s Buffalo Neuroimaging Analysis Center (BNAC) played a pivotal role in a phase III clinical trial of the first transcatheter cerebral embolic protection (TCEP) device to obtain marketing clearance by the Food and Drug Administration.
